Biopharma therapeutics and platforms venture funding cooled in Q3 2026: fewer, smaller rounds, a tilt toward later-stage companies, and the biggest checks for clinical-stage programs.
Venture Funding Activity. Companies raised $6.7B across 118 rounds, down from $9.9B across 139 rounds in Q2. Capital fell 32.3%, and the number of rounds fell 15.1%, while the average round shrank 22.2% to $63M from $81M.
Series D and beyond funding rose 157.1% to $1.8B, and series C gained 9.1% to $1.2B. In contrast, series B fell the most, down 66.7% to $1.3B, followed by rounds with no disclosed series, down 62.5% to $600M. Series A declined 30.4% to $1.6B and seed 33.3% to $200M. Over Q2 and Q3 combined, series B still led with $5.2B, ahead of series A at $3.9B.
The leading therapy areas drew $3.7B across 74 rounds, 54.6% of all Q3 funding. Cancer led with $1,033M across 14 rounds, and neurology followed with $843M across 17 rounds, together taking 51.3% of the total for these areas. Autoimmune disease ranked third at $420M, ahead of eye disease at $377M and lung disease at $269M.
The leading drug types drew $3.8B across 81 rounds, 57.1% of all Q3 funding. Small molecules led with $1.9B across 36 rounds, and biologics followed with $1.1B across 24 rounds, together taking 78.1% of the total for these types. Gene therapy ranked third with $476M across 8 rounds, ahead of cell therapy at $295M across 10 rounds.
Encoded Therapeutics led with a $275M series F to fund a pivotal trial of its Dravet syndrome gene therapy. Solstice Oncology launched with a $225M series A to test immunotherapy porustobart before colon cancer surgery. LifeMine Therapeutics’ $188M series E drew Bezos Expeditions and Gates Frontier to back an anti-rejection drug for organ transplants. Celea Therapeutics raised $180M at a $303M post-money valuation for the first head-to-head Phase 3 trial in idiopathic pulmonary fibrosis. Vaderis Therapeutics’ $152M series B funds a Phase 3 trial in hereditary hemorrhagic telangiectasia, a rare blood vessel disorder.
Biopharma therapeutics and platforms venture funding slowed in Q3 2026, with 118 rounds raising $6.7B. Against Q2’s 139 rounds and $9.9B, round count fell 15.1%, and capital raised dropped 32.3%. Average round size also declined 22.2%, to $63M from $81M, so rounds were smaller as well as fewer. Across Q2 and Q3, the sector recorded 257 rounds and $16.5B in reported capital.
Biopharma Therapeutics and Platforms Venture Funding Activity by Series
Biopharma therapeutics and platforms venture funding declined in Q3 2026, with 118 rounds raising $6.7B against 139 rounds and $9.9B in Q2. Round count fell 15.1%, while total funding dropped 32.3%. Later-stage rounds bucked the trend. Series D and beyond funding rose 157.1% to $1.8B from $700M, and series C gained 9.1% to $1.2B from $1.1B. In contrast, series B posted the steepest drop, falling 66.7% to $1.3B from $3.9B. Unspecified private funding followed, down 62.5% to $600M from $1.6B. Series A fell 30.4% to $1.6B from $2.3B, while seed funding declined 33.3% to $200M from $300M. Across Q2 and Q3 combined, the sector recorded 257 rounds raising a reported $16.5B. Series B attracted the most capital at $5.2B, followed by series A at $3.9B.
Biopharma Therapeutics and Platforms Venture Funding Activity by Top Therapy Areas – Q3 2026
In Q3 2026, the top therapy areas attracted $3.7B of biopharma therapeutics and platforms venture funding across 74 rounds. That represents 54.6% of the sector’s $6.7B total. Cancer led with $1,033M across 14 rounds, a 28.3% share of top therapy area funding. Neurology followed with $843M across 17 rounds, a 23.1% share. Autoimmune ranked third with $420M, ahead of ophthalmic ($377M), pulmonary ($269M), infectious diseases ($253M), and endocrine/metabolic ($192M). Smaller amounts went to musculoskeletal ($95M), cardiovascular ($78M), renal ($46M), dermatologic ($44M), and gastrointestinal ($5M). Investment was concentrated at the top: cancer and neurology together captured 51.3% of funding across the listed therapy areas.
Biopharma Therapeutics and Platforms Venture Funding Activity by Top Modalities – Q3 2026
In Q3 2026, the top modalities attracted $3.8B of biopharma therapeutics and platforms venture funding across 81 rounds. That is 57.1% of the sector’s $6.7B total. Small molecules led with $1.9B across 36 rounds, capturing nearly half of top modality funding at 48.8%. Biologics (antibodies, DNA, RNA, and proteins) followed with $1.1B across 24 rounds (29.3%). Gene therapy and vectors ranked third with $476M across 8 rounds (12.4%). Cell therapy came next with $295M across 10 rounds (7.7%). Immunotherapy attracted $66M across 2 rounds, while gene editing/CRISPR drew $3M from a single round. Together, small molecules and biologics took 78.1% of top modality funding.
Top Biopharma Therapeutics and Platforms Venture Funding in Q3 2026
Encoded Therapeutics – Series F – $275M – September 2026
Encoded Therapeutics raised a $275M series F in September 2026, co-led by GV and an undisclosed healthcare fund. ARCH Venture Partners, RTW Investments, SoftBank Vision Fund 2, and Venrock also participated. Proceeds will fund pivotal development of ETX101, a one-time AAV9 gene regulation therapy that boosts SCN1A expression in inhibitory interneurons, for SCN1A-positive Dravet syndrome. In Phase 1/2 POLARIS, the top two doses cut median monthly seizure frequency by about 79% (n=3) and 89% (n=5) at Month 12. The Breakthrough Therapy-designated candidate has shown no treatment-related serious adverse events. The round also funds in-house commercial-scale manufacturing and advances ETX301 toward a planned 2027 IND in post-amputation neuroma pain.
Solstice Oncology – Series A – $225M – September 2026
Solstice Oncology launched in September 2026 with a $225M series A led by RA Capital Management, joined by Canaan Partners and Forbion. In February 2026, it in-licensed ex-Greater China rights to porustobart, a second-generation, Fc-enhanced CTLA-4 antibody, from Harbour BioMed. Harbour secured over $105M in upfront consideration, including equity, plus up to about $1.1B in milestones. In Harbour’s Phase 2, porustobart plus tislelizumab produced a 30% response rate in late-line microsatellite-stable (MSS) metastatic colorectal cancer without liver metastases. Solstice plans to open enrollment in early Q4 2026 for a neoadjuvant Phase 2 with pembrolizumab in MSS stage II and III colon cancer. Data are expected in the H2 of 2027.
LifeMine – Series E – $188M – July 2026
LifeMine Therapeutics closed an oversubscribed $188M series E in July 2026, led by Milky Way Investments. Bezos Expeditions, Gates Frontier, and RA Capital Management joined as new investors alongside GV, GSK, and ARCH Venture Partners. With a previously undisclosed $75M series D, new capital totals $263M, bringing total funding to $558M. Proceeds advance LIFE-001, a long-acting injectable calcineurin activation inhibitor designed to prevent transplant rejection without the organ toxicity of tacrolimus and cyclosporine. A Phase 1 study in more than 120 adults has shown no clinically meaningful renal, metabolic, or cardiovascular safety signals. A Phase 2 kidney transplant study and a Phase 1b islet cell transplant study are planned.
Celea Therapeutics – Series Unspecified – $180M – July 2026
PureTech-founded Celea Therapeutics completed a $180M financing in July 2026 at a $303M fully diluted post-money valuation. RA Capital Management, Leaps by Bayer, PureTech, a large US healthcare fund, and a sovereign wealth fund participated. PureTech contributed $30M and holds a 35.4% stake, plus royalties and up to $190M in sales milestones. Its lead asset, deupirfenidone, is a deuterated form of pirfenidone for idiopathic pulmonary fibrosis (IPF). In Phase 2b ELEVATE IPF, the 825 mg dose limited 26-week FVC decline to 21.5 mL, versus 112.5 mL on placebo and 51.6 mL on pirfenidone. Proceeds fund SURPASS-IPF, the first head-to-head Phase 3 in IPF, testing superiority over pirfenidone on 52-week FVC.
Vaderis Therapeutics – Series B – $152M – August 2026
Basel-based Vaderis Therapeutics closed an oversubscribed $152M series B in August 2026, co-led by Life Sciences at Goldman Sachs Alternatives and TCGX. Omega Funds, EQT Life Sciences, Perceptive Advisors, and Kalehua Capital joined existing backers Medicxi and Droia. Engasertib, its lead asset, is a once-daily oral allosteric AKT1/2 inhibitor for hereditary hemorrhagic telangiectasia (HHT), a rare genetic vascular disorder with no approved therapies. In a 75-patient, 12-week proof-of-concept study published in NEJM, 40 mg engasertib cut nosebleed duration by 41% and frequency by 28%, versus 24% and 18% on placebo. Proceeds fund the global, placebo-controlled Phase 3 HEROIC study, launched with the round, and operations through potential US approval.
Also check out Biopharma Therapeutics and Platforms M&A – Q3 2026 Review
